Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine ...

The most important take-home information from the INTERLACE trial is that in some people with cervical cancer that are ...

Integrated care involving medication and intensive counseling showed effectiveness for smoking cessation among adults ...

The Gliofocus Study is now open in Paris and Madrid. The global Gliofocus network includes 68 EU medical centers. In the ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Like many cancer patients, Michael Wolff wanted answers. But, like many cancer patients in 2015, he wasn't getting them.

Signet Therapeutics ("Signet"), a clinical-stage biotech company leveraging organoids and AI to develop first-in-class cancer therapies, today announced that the first patient has been dosed in the ...

'It finished three days before Christmas. I was sleeping on Christmas day,' she said. Two weeks later and she has finally ...

A cancer dietician has shared a list of items she says are safe to eat and drink without increasing the risk of developing ...

An AI system developed to predict a patient's response to immunotherapy could help "democratize" access to the pricey drugs ...

Hina Khan discusses her challenging 15-hour surgery experience during cancer treatment. Discover her journey and insights.- ...